Binge-Eating Disorder Treatment Market By Treatment Type (Psychological & Behavioral Therapy, Pharmacotherapy, Guided Self-Help & Group Therapy, Multidisciplinary Supportive Care); By Care Delivery Model (In-Person Outpatient Care, Telehealth & Virtual Therapy, Hybrid Care Programs, Digital Therapeutic Platforms); By End User (Specialty Eating-Disorder Clinics, Outpatient Therapy Centers, Hospitals & Health Systems, Digital Mental Health Platforms); By Patient Group (Adults With Moderate-to-Severe BED, Patients With Psychiatric Comorbidities, Patients With Obesity & Metabolic Comorbidities, Adolescents); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Binge Eating Disorder Treatment Market: Therapy Access, Generic Competition, and Integrated Care Reshape Treatment Economics

The Global Binge Eating Disorder Treatment Market was valued at USD 716.8 million in 2025 and is projected to reach USD 1.23 billion by 2032, growing at a CAGR of 8.06%, according to Strategic Market Research.

 

The binge eating disorder treatment market includes psychological therapy, guided self-help, psychiatric consultations, nutritional support, telehealth care, and pharmacotherapy for selected adults. Providers generate revenue through diagnostic assessments, completed therapy sessions, multidisciplinary treatment courses, medication-management visits, digital-care contracts, and recurring prescriptions.

 

Behavioral care remains the principal treatment pathway. Cognitive behavioral therapy and other structured psychological interventions are available to a broader diagnosed population than medication, while pharmacotherapy is generally reserved for adults with moderate-to-severe symptoms, treatment preference, psychiatric comorbidities, or an inadequate response to psychotherapy.

 

Global Patient Numbers Exceed the Diagnosed and Treated Population

A Global Burden of Disease extension estimated that approximately 17.3 million people were living with binge eating disorder in 2019. Separate multinational surveys have placed average lifetime prevalence near 1.9%, although results vary according to diagnostic criteria, study period, age group, and geography.

U.S. National Comorbidity Survey data reported past-year adult prevalence of 1.2% and lifetime prevalence of 2.8%, supporting estimates that several million American adults experience BED. Historical lifetime prevalence reached 3.5% among women and 2.0% among men.

BED affects men more frequently than anorexia nervosa or bulimia nervosa relative to women, but male patients remain less likely to receive eating-disorder screening or enter specialist care. Providers that continue to position services mainly toward young women risk overlooking a substantial adult male patient group.

Symptoms often begin before patients establish regular contact with behavioral-health specialists. The median age of onset in U.S. survey data was 21 years, while approximately 1.6% of adolescents aged 13–18 had experienced the condition. Earlier research estimated an average illness duration of around eight years, leaving many patients in primary care, obesity management, endocrinology, or general psychiatry without a BED-specific diagnosis.

 

Psychiatric Comorbidities Increase the Intensity of Care

Approximately 78.9% of adults with BED in the U.S. survey had at least one additional psychiatric disorder. Anxiety disorders affected 65.1%, mood disorders 46.4%, impulse-control disorders 43.3%, and substance-use disorders 23.3%.

Comorbid depression, anxiety, trauma, and substance use increase demand for psychiatric assessment, medication review, suicide-risk evaluation, and individualized therapy. Providers treating only eating behavior may lose patients who also require broader mental-health support.

Functional impairment also narrows the gap between epidemiological prevalence and clinically meaningful need. Some degree of impairment was reported by 62.6% of affected adults, while 18.5% experienced severe impairment. Patients with greater functional disruption are more likely to require specialist intervention, longer treatment courses, and coordinated care.

BED frequently overlaps with overweight, obesity, diabetes risk, and cardiovascular disease, but body weight alone does not define the disorder. Weight-management programs that do not address recurrent loss-of-control eating, emotional triggers, and restrictive dieting cycles may fail to resolve the behavioral condition. Coordination between eating-disorder specialists, obesity clinicians, primary-care physicians, and endocrinologists can improve referral conversion and broaden access.

 

Most Patients Never Enter BED-Specific Treatment

Only 43.6% of U.S. adults with lifetime BED reported ever seeking treatment specifically for an eating disorder. Treatment seeking reached 50.8% among women but only 28.9% among men.

Stigma, poor symptom recognition, fear of weight-related judgment, therapist shortages, and incomplete insurance coverage reduce the number of patients entering professional care. Many patients first seek help for depression, anxiety, obesity, or metabolic disease without discussing binge episodes.

Claims activity indicates that formal recognition is improving. FAIR Health reported an 81% increase in U.S. BED medical claim lines between 2018 and 2022. BED-only patients represented 24.3% of eating-disorder patients in its private-claims dataset.

Claim lines measure billed services rather than unique patients and do not represent the entire U.S. population. Even with those limitations, rising claims indicate more diagnostic assessments, therapy encounters, psychiatric consultations, and follow-up visits moving into reimbursed care.

 

Therapy Courses Generate the Largest Share of Treatment Revenue

Psychological treatment produces multi-session revenue rather than a one-time consultation. NICE recommends BED-focused guided self-help supported by approximately four to nine brief sessions over about 16 weeks. Patients requiring more intensive care may receive 16 weekly group CBT sessions or approximately 16–20 individual CBT sessions.

Guided self-help allows clinics and digital providers to serve more patients with fewer specialist hours. Structured materials, symptom monitoring, food-pattern exercises, and short clinician contacts can reduce the cost per treated patient while preserving professional oversight.

Group CBT offers similar capacity advantages because one clinician can treat several patients during the same session. Health systems and insurers facing long waiting lists may favor group formats where clinical suitability and patient acceptance are adequate.

Individual CBT generates higher revenue per treatment episode but requires more psychologist time. Patients with severe symptoms, trauma histories, social difficulties, or complex psychiatric comorbidities are more likely to require individualized care.

Interpersonal psychotherapy, psychiatric management, and dietetic support increase treatment value when they are incorporated into multidisciplinary care. Providers with coordinated psychological, psychiatric, and nutritional services can retain more of the patient journey, although fragmented reimbursement and workforce costs may reduce margins.

 

Telehealth Expands Reach but Still Depends on Clinician Capacity

BED treatment is well suited to remote delivery because assessment, therapy, behavioral monitoring, and follow-up generally occur outside hospitals. Virtual care removes geographic barriers and gives patients access to eating-disorder clinicians who may not be available locally.

Across all eating-disorder claim lines in FAIR Health’s dataset, telehealth increased from 0.3% of place-of-service activity in 2018 to 35.7% in 2022. The measure is not limited to BED, but it confirms that a substantial share of eating-disorder care can move online when reimbursement and licensed providers are available.

Clinically supported digital programs have stronger positioning than stand-alone food-tracking or wellness applications. Insurers and health systems need evidence of treatment completion, reduced binge frequency, risk monitoring, and clear escalation routes for patients with severe depression, suicidality, or substance use.

Virtual delivery improves geographic reach but does not remove the need for qualified psychologists, psychiatrists, and dietitians. Digital providers still compete for scarce clinicians and must maintain patient engagement across several weeks or months of treatment.

 

Reimbursement Does Not Guarantee Treatment Initiation

Australia provides one of the clearest examples of a publicly funded eating-disorder treatment pathway. Eligible patients can receive up to 40 psychological and 20 dietetic services within 12 months.

Between the program’s introduction in 2019 and the end of 2022, 544,368 services were claimed, including 330,376 psychological-treatment services and 145,144 dietetic services. These figures cover multiple eating disorders and cannot be assigned to BED alone.

Only 67.3% of treatment-plan clients received at least one treatment service. Psychological care reached 53.0%, dietetic care reached 44.5%, and 30.2% received both.

Provider shortages, administrative requirements, referral complexity, benefit gaps, and patient affordability prevented many eligible patients from progressing into treatment. Forecasts based on maximum annual allowances would therefore overstate actual utilization.

Completed sessions provide a more reliable measure of commercial demand than treatment-plan creation or theoretical coverage. Payers may authorize extensive care, but provider availability and patient continuation determine realized revenue.

 

Lisdexamfetamine Faces Structural Price Pressure

Lisdexamfetamine remains the only FDA-approved active pharmaceutical ingredient specifically indicated for moderate-to-severe BED in adults. Daily administration creates recurring prescription demand, although the eligible population is narrower than the broader psychotherapy population.

Stimulant-related risks, contraindications, controlled-substance monitoring, payer restrictions, and patient preference reduce initiation and persistence. Lisdexamfetamine is also not approved as an obesity or weight-loss treatment.

The FDA approved multiple first generic lisdexamfetamine products in August 2023. Generic availability can improve affordability and formulary acceptance, while pharmacy substitution weakens branded pricing and shifts purchasing power toward payers.

Takeda reported material Vyvanse revenue pressure from U.S. generic competition during FY2025. Company sales cannot be used as BED revenue because Vyvanse is prescribed much more widely for attention-deficit/hyperactivity disorder.

Arynta, a lisdexamfetamine oral solution, received FDA approval in June 2025 for ADHD and moderate-to-severe adult BED. The liquid format may benefit patients who have difficulty swallowing capsules or need an alternative administration method.

Arynta competes through formulation convenience rather than a new mechanism or improved BED efficacy. Generic capsules will continue to dominate price-sensitive use, while the oral solution is more likely to serve a smaller administration-specific patient group.

 

Combination Treatment Increases Episode Value

A randomized trial involving 141 adults with BED and obesity compared CBT, lisdexamfetamine, and combined treatment. Binge-eating remission reached 70.2% with CBT plus lisdexamfetamine, compared with 44.7% for CBT and 40.4% for lisdexamfetamine alone.

Combined treatment can generate psychological therapy revenue, psychiatric monitoring, and recurring prescriptions within the same patient episode. Specialist networks capable of coordinating both pathways may capture more revenue than isolated therapy or prescribing practices.

The study was conducted at one site over 12 weeks, limiting direct application to routine care. Payer adoption will depend on longer-term outcomes, treatment persistence, provider coordination, and whether the additional cost produces durable reductions in binge episodes and psychiatric impairment.

 

Solriamfetol Leads the Development Pipeline

Solriamfetol is the most advanced investigational drug for BED. Axsome Therapeutics is conducting the Phase 3 ENGAGE trial in approximately 450 adults, with topline results expected during the second half of 2026.

Approval during 2027 would require positive results, rapid submission, and an efficient regulatory review. A 2028 launch remains a more realistic analyst estimate, subject to safety findings, clinical outcomes, and FDA requirements.

A successful solriamfetol program would introduce active-ingredient competition into a pharmaceutical segment currently centered on lisdexamfetamine. Prescriber uptake would depend on comparative efficacy, tolerability, controlled-substance status, payer coverage, and positioning alongside psychotherapy.

TNX-1900, an intranasal oxytocin formulation associated with Tonix Pharmaceuticals and Massachusetts General Hospital, remains in Phase 2 evaluation. Successful Phase 2 and Phase 3 development would still be required, placing any potential approval no earlier than 2029–2031.

Bioprojet’s BP1.4979 completed a pilot Phase 2 study, while Otsuka’s centanafadine completed a Phase 2 BED trial involving 147 adults. Neither candidate has a publicly established Phase 3 BED program, making commercial progression uncertain.

Semaglutide and other GLP-1 medicines are being explored among patients with BED and obesity. Current evidence remains early and largely investigator-led. No dedicated registrational BED program has established disorder-specific efficacy, psychiatric safety, durability, or a regulatory pathway.

 

Impactful Market Segments

Psychological and Behavioral Therapy

Psychological therapy represents the largest treatment segment because it applies across mild, moderate, and severe diagnosed cases. Guided self-help and group CBT improve patient throughput, while individual CBT and interpersonal psychotherapy generate higher revenue per treatment episode. Segment growth depends on clinician availability, payer coverage, referral conversion, and patient completion rather than diagnosed prevalence alone.

Pharmacotherapy

Generic lisdexamfetamine accounts for the main current drug volume, while branded and liquid formulations compete through administration convenience and patient familiarity. Generic substitution is reducing molecule-level pricing power. Solriamfetol offers the most advanced opportunity for new active-ingredient competition, while other pipeline candidates remain early-stage or commercially uncertain.

Outpatient and Virtual Care

Outpatient practices, eating-disorder clinics, and telehealth providers deliver most BED treatment. Virtual programs expand geographic reach and support guided self-help, group therapy, and medication follow-up. Providers with short waiting times, licensed specialists, payer contracts, and escalation pathways have stronger positioning than wellness applications without integrated clinical care.

 

Patients With Psychiatric and Metabolic Comorbidities

Adults with anxiety, depression, obesity, diabetes risk, trauma, or substance-use disorders generate higher treatment intensity because they require coordinated behavioral, psychiatric, nutritional, and medical care. Men remain an underdiagnosed segment because treatment-seeking is considerably lower despite meaningful prevalence. Adolescents require earlier intervention, family involvement, and age-appropriate behavioral services.

 

Commercial Growth Depends on Treatment Conversion

BED prevalence substantially exceeds the number of diagnosed and treated patients. Revenue growth therefore depends on screening, referral, provider capacity, reimbursement, and treatment completion.

Primary-care physicians, obesity clinicians, diabetes services, universities, and general psychiatrists can expand diagnosis by screening patients with recurrent loss-of-control eating. Specialist services must add capacity at the same time or referrals will continue to accumulate without converting into completed care.

Behavioral providers benefit from multi-session treatment demand but face workforce shortages and reimbursement limits. Drug manufacturers gain recurring prescription revenue from a smaller patient group and face generic substitution, stimulant-monitoring requirements, and payer controls.

Integrated providers can improve patient retention by combining early identification, guided low-intensity care, specialist therapy, psychiatric prescribing, and management of depression, anxiety, obesity, and other comorbidities.

 

Binge-Eating Disorder Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 716.8 Million
Revenue Forecast in 2032	USD 1.23 Billion
Overall Growth Rate	CAGR of 8.06% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Care Delivery Model, By End User, By Patient Group, By Geography
By Treatment Type	Psychological & Behavioral Therapy, Pharmacotherapy, Guided Self-Help & Group Therapy, Multidisciplinary Supportive Care
By Care Delivery Model	In-Person Outpatient Care, Telehealth & Virtual Therapy, Hybrid Care Programs, Digital Therapeutic Platforms
By End User	Specialty Eating-Disorder Clinics, Outpatient Therapy Centers, Hospitals & Health Systems, Digital Mental Health Platforms
By Patient Group	Adults With Moderate-to-Severe BED, Patients With Psychiatric Comorbidities, Patients With Obesity & Metabolic Comorbidities, Adolescents
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Market Drivers	Rising diagnosis and screening of binge-eating disorder Wider access to structured psychological therapy Expansion of telehealth and integrated behavioral care
Customization Option	Available upon request